10996 Torreyana Road
Tel: (858) 764-4290
About Expansion Therapeutics
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. We are initially focused on expansion repeat disorders, a set of ~30 genetic diseases for which there are no satisfactory therapies. Our lead disease focus, myotonic dystrophy type 1 (DM1), is the most frequent cause of adult onset muscular dystrophy. Expansion has assembled an initial focused pipeline of compositions targeting repeats that drive a number of expansion repeat disorders. For more information or to apply for this position, please visit our website htttps://www.expansionrx.com
2 articles with Expansion Therapeutics
Origenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics for Novel Therapies Targeting RNA-mediated Diseases
Companies Initiate Lead Optimization Program Leveraging the Origenis AI Discovery Platform to Identify RNA-targeted Small Molecule Compounds for Development
Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.